Ara
Toplam kayıt 10, listelenen: 1-10
QTc Prolongation During Peripheral Stem Cell Apheresis in Healthy Volunteers
(2017)
Background and aim: Today, voluntary donation of peripheral blood stem cells by healthy donors for allogeneic hemopoietic cell transplantation is common worldwide. Such donations are associated with small but measurable ...
Second Malignancies İn Philadelphia-Positive and -Negative Myeloproliferative Neoplasms: A Single Center Study
(2016)
Introduction: Leukemic transformation (LT) of both Philadelphia (Ph) -positive and -negative myeloprolifetarive neoplasms (MPNs) is a well-known subject. However sufficient data are not available in literature from Turkey ...
Red Blood Cell Exchange Followed by Plasma Exchange in Patients with Intrahepatic Cholestasis due to Sickle Cell Disease
(2016)
Intrahepatic cholestasis, a rare complication of sickle cell anemia, is characterized by marked hyperbilirubinemia, acute hepatic failure, and an often fatal course. In this report, we present patients with homozygous ...
Frequency of Finding Family Donors: A Single Center Experience
(2018)
Objectives: Allogeneic hematopoietic stem cell transplant is a curative treatment option for many hematologic diseases. The existence of a fully compatible donor for recipients is the first condition for minimized ...
The Impact of the Ferric Carboxymaltose on Hemoglobin and Ferritin Levels
(2020)
Background: Anemia is a frequent disorder worldwide. Iron deficiency anemia (IDA) is the most common form of anemia. Although oral iron is the first choice for treatment, the efficacy of oral iron preparations may be ...
A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity
(2020)
In this multicenter retrospective study, we compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) preparation regimens. The 3-year expected overall ...